‘Pharma companies make money on a new drug by selling a lot or charging a lot - but with antimicrobials neither is possible.’ - Andrew Bowskill #AAMRNet.
Delinking funding from use is the only way to stimulate investment in new antimicrobials #MTPConnect #AMR #antimicrobials @drewabow.bsky.social

Surveillance of antimicrobial use and resistance ‘in isolation is like counting raindrops in a thunderstorm’ - we need more investment in innovation and prevention of AMR. Dr Richard Alm
Speaking in Adelaide #MTPConnect #AAMRNet #AMR #PublicHealth #antimicrobials @carb-x.bsky.social

High value opportunities were also identified, including innovative, advanced therapies such as cell and gene therapies.

It’s an exciting time to be in biotech and medtech folks! Congrats Rebekah Cassidy and Stuart Dignam and all involved.

#AusBiotech #MTPConnect

Areas discussed included enabling and scaling commercialisation, market access, regulatory pathways, manufacturing, procurement, investment, raising capital, horizon-scanning, workforce development, collaboration, knowledge-sharing, infrastructure, clinical trials and more. #AusBiotech #MTPConnect

Courageous conversations were had in Canberra this week.

It was excellent to be in the room for the National Biotech Medtech Development Summit co-hosted by #AusBiotech and #MTPConnect.

All ideas were on the table during this dynamic national conversation.